GlassScriptPhysician profile
Vipan K Gupta
NPI 1356393730
$5,743.46
in general payments reported to CMS, 2019-2025
29 companies · $359 in 2025
The $359 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,092 · 2020: $38.93 · 2021: $1,457 · 2022: $708 · 2023: $1,996 · 2024: $91.33 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,088 · Food and Beverage: $884 · Consulting Fee: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,087.98 |
| Food and Beverage | $883.59 |
| Consulting Fee | $475.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,705.08 | 2019-2023 | Vns Therapy |
| Catalyst Pharmaceuticals, INC. | $1,125.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $732.78 | 2019-2025 | Ultomiris |
| Biogen, INC. | $609.81 | 2019-2025 | Tysabri |
| Banner Life Sciences, LLC | $331.53 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $245.15 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $195.59 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $137.88 | 2019 | |
| Argenx US, INC. | $91.33 | 2024 | Vyvgart |
| Merck Sharp & Dohme LLC | $85.85 | 2019 | |
| Emd Serono, INC. | $85.47 | 2019 | |
| Ucb, INC. | $39.60 | 2019 | |
| Promius Pharma LLC | $38.49 | 2019 | |
| Cycle Pharmaceuticals INC | $33.86 | 2025 | Bafiertam |
| Lilly USA, LLC | $23.99 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.62 | 2019 | |
| Abbvie INC. | $22.69 | 2022 | |
| Assertio Therapeutics, INC. | $22.55 | 2019 | |
| Akcea Therapeutics, INC. | $22.22 | 2019 | |
| Acadia Pharmaceuticals INC | $21.66 | 2019 | |
| Sunovion Pharmaceuticals INC. | $21.57 | 2019 | |
| Supernus Pharmaceuticals, INC. | $20.47 | 2019 | |
| Genzyme Corporation | $19.86 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.13 | 2019 | |
| Amneal Pharmaceuticals LLC | $17.37 | 2019 | |
| Vertical Pharmaceuticals, LLC | $15.56 | 2019 | |
| Corium, LLC | $14.32 | 2022 | |
| Allergan, INC. | $11.21 | 2019 | |
| Genentech USA, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vipan Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.